Structural biology of SARS-CoV-2: open the door for novel therapies
W Yan, Y Zheng, X Zeng, B He, W Cheng - Signal Transduction and …, 2022 - nature.com
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …
[HTML][HTML] Coronavirus biology and replication: implications for SARS-CoV-2
P V'kovski, A Kratzel, S Steiner, H Stalder… - Nature Reviews …, 2021 - nature.com
The SARS-CoV-2 pandemic and its unprecedented global societal and economic disruptive
impact has marked the third zoonotic introduction of a highly pathogenic coronavirus into the …
impact has marked the third zoonotic introduction of a highly pathogenic coronavirus into the …
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
F Kabinger, C Stiller, J Schmitzová… - Nature structural & …, 2021 - nature.com
Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …
Coronavirus vaccine development: from SARS and MERS to COVID-19
Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of
coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the …
coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the …
SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …
The architecture of SARS-CoV-2 transcriptome
D Kim, JY Lee, JS Yang, JW Kim, VN Kim, H Chang - Cell, 2020 - cell.com
SARS-CoV-2 is a betacoronavirus responsible for the COVID-19 pandemic. Although the
SARS-CoV-2 genome was reported recently, its transcriptomic architecture is unknown …
SARS-CoV-2 genome was reported recently, its transcriptomic architecture is unknown …
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
J Osipiuk, SA Azizi, S Dvorkin, M Endres… - Nature …, 2021 - nature.com
The pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
2) continues to expand. Papain-like protease (PLpro) is one of two SARS-CoV-2 proteases …
2) continues to expand. Papain-like protease (PLpro) is one of two SARS-CoV-2 proteases …
Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex
SARS-CoV-2 is the causative agent of the 2019–2020 pandemic. The SARS-CoV-2 genome
is replicated and transcribed by the RNA-dependent RNA polymerase holoenzyme …
is replicated and transcribed by the RNA-dependent RNA polymerase holoenzyme …
[HTML][HTML] The coding capacity of SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing
coronavirus disease 2019 (COVID-19) pandemic 1. To understand the pathogenicity and …
coronavirus disease 2019 (COVID-19) pandemic 1. To understand the pathogenicity and …
Structure of replicating SARS-CoV-2 polymerase
The new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses
an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the …
an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the …